LONG ISLAND CITY, N.Y.--(BUSINESS WIRE)--Sirona (Nasdaq: SIRO), the dental technology leader, today announced its financial results for the quarter and fiscal year ended September 30, 2011.
Fourth Quarter Fiscal 2011 vs. Fourth Quarter Fiscal 2010 Financial Results
Revenue was $218.8 million, an increase of $35.9 million or up 19.6% (up 11.8% on a constant currency basis), with growth rates for the Company's business segments as follows: Imaging Systems increased 42.9% (up 37.1% constant currency); CAD / CAM increased 10.9% (up 3.9% constant currency); Instruments increased 11.3% (up 1.6% constant currency); and Treatment Centers increased 2.7% (down 6.4% constant currency). Revenue in the United States increased 13.5%, while revenues outside the United States increased 21.9% (up 11.3% constant currency), with strong growth in Asia Pacific and the Middle East.
Gross profit was $110.7 million, up $17.6 million. Gross profit margin was 50.6% in the fourth quarter of Fiscal 2011, compared to 50.9% in the prior year. Gross profit margin as a percent of sales was impacted by product mix and the strengthening of the Euro relative to the Dollar.
Fourth quarter 2011 operating income excluding amortization expense and a one-time, non-cash compensation charge was $45.5 million (operating income of $25.0 million plus amortization expense of $13.9 million, plus the $6.6 million charge), compared to $37.9 million (operating income of $23.2 million plus amortization expense of $14.7 million) in the fourth quarter of 2010.
Net income for the fourth quarter of 2011 was $13.8 million, or $0.24 per diluted share, versus $24.7 million, or $0.44 per diluted share in the prior year period. Non-GAAP earnings per diluted share for the fourth quarter of 2011 was $0.68 compared to $0.44 in the fourth quarter of 2010.
At September 30, 2011, the Company had cash and cash equivalents of $345.9 million and total debt of $368.4 million, resulting in net debt of $22.5 million. This compares to net debt of $119.0 million at September 30, 2010.
Jost Fischer, Chairman and CEO of Sirona commented: “I am delighted to report that fiscal 2011 was a very successful year for Sirona. We posted record revenues and earnings, strengthened our balance sheet, introduced exciting new products, and had an impressive showing at the International Dental Show. Our new products demonstrate the Company’s continued focus on innovation and the benefits we derive from our industry-leading investments in research and development. These factors, plus our ongoing initiatives to build out our global sales and service infrastructure position us well to compete and win in fiscal 2012 and beyond.”
Fiscal 2012 Guidance
Management anticipates fiscal 2012 revenue growth in the range of 6% to 8% on a constant currency basis, and operating income, excluding amortization estimated at $52 million, to be in the range of $225 to $234 million.
Fiscal 2011 vs. Fiscal 2010 Financial Results
Revenue was $913.9 million, an increase of $143.6 million, or 18.6% (up 16.4% constant currency) with growth rates for the Company's business segments as follows: Imaging Systems increased 26.6% (up 24.8% constant currency); CAD/CAM increased 17.8% (up 15.9% constant currency); Treatment Centers increased 13.3% (up 10.2% constant currency); and Instruments increased 8.5% (up 5.6% constant currency). Revenue in the United States increased 6.8% compared to prior year, driven by the Imaging and CAD/CAM segments. Outside the United States, revenue increased 24.0% (up 20.5% constant currency). Revenue growth was particularly strong in Europe, led by Germany, as well as in the Asia-Pacific markets.
Gross profit increased by $84.6 million to $483.7 million, up 21.2%. Gross profit margin of 52.9% was up 110 basis points compared to the prior year, mainly driven by lower levels of deal related amortization.
Fiscal 2011 operating income excluding amortization expense and a one-time, non-cash compensation charge was $222.5 million (operating income of $160.9 million plus amortization expense of $54.9 million, plus the $6.6 million charge). This compares to 2010 operating income excluding amortization expense of $188.9 million (operating income of $128.1 million plus amortization expense of $60.8 million).
Conference Call/Webcast Information
Sirona will hold a conference call to discuss its financial results at 8:30 AM Eastern Time on November 18, 2011. The teleconference can be accessed by calling +1 866 271 0675 (domestic) or +1 617 213 8892 (international) using passcode # 55073002. The webcast will be available via the Internet at http://ir.sirona.com and a presentation relating to the call will be available on our website. A replay of the conference call will be available through November 25, 2011 by calling +1 888 286 8010 (domestic) or +1 617 801 6888 (international) using passcode # 36894426. A web archive will be available for 30 days at www.sirona.com.
About Sirona Dental Systems, Inc.
Sirona, the dental technology leader, has served dealers and dentists worldwide for more than 130 years. Sirona develops, manufactures, and markets a complete line of dental products, including CAD/CAM restoration systems (CEREC), digital intra-oral, panoramic and 3D imaging systems, dental treatment centers and handpieces. Visit http://www.sirona.com for more information about Sirona and its products.
This press release contains forward-looking information about Sirona Dental Systems, Inc.’s financial results, guidance and estimates, business prospects, and products and services that involve substantial risks and uncertainties or other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. You can identify these statements by the use of words such as "may," "could," "estimate," "will," "believe," "anticipate," "think," "intend," "expect," "project," "plan," "target," "forecast", and similar words and expressions which identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and involve known and unknown risks and uncertainties, and other factors. Readers are cautioned not to place undue reliance on such statements, which speak only as of the date hereof. For a discussion of such risks, uncertainties and other matters that could cause actual results to differ materially, including risks relating to, among other factors, the market for dental product and services, pricing, future sales volume of the Company's products, the possibility of changing economic, market and competitive conditions, dependence on products, dependence on key personnel, technological developments, intense competition, market uncertainties, dependence on distributors, ability to manage growth, dependence on key suppliers, dependence on key members of management, government regulation, acquisitions and affiliations and currency exchange rate fluctuations, readers are urged to carefully review and consider various disclosures made by the Company in its Annual Report on Form 10-K and in its reports on Forms 10-Q and 8-K filed with the U.S. Securities and Exchange Commission, which can be accessed through the SEC’s website, www.sec.gov. This presentation contains non GAAP financial measures, which should not be viewed in isolation and do not purport to be an alternative to net income (loss) as an indicator of operating performance or an alternative to cash flows from operating activities as a measure of liquidity. The Company assumes no obligation to and expressly disclaims any obligation to update or revise any forward-looking statements contained in this document to reflect new information or future events or developments after the date any such statement is made.
|
SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES CONSOLIDATED INCOME STATEMENT |
|||||||||||||
| UNAUDITED | |||||||||||||
| Quarter ended | Quarter ended | Year ended | Year ended | ||||||||||
| September 30, | September 30, | September 30, | September 30, | ||||||||||
| 2011 | 2010 | 2011 | 2010 | ||||||||||
| $'000s (except per share amounts) | |||||||||||||
| Revenue | $ | 218,797 | $ | 182,899 | $ | 913,866 | $ | 770,276 | |||||
| Cost of sales | 108,080 | 89,767 | 430,214 | 371,266 | |||||||||
| Gross profit | 110,717 | 93,132 | 483,652 | 399,010 | |||||||||
| Selling, general and administrative expense | 74,637 | 60,732 | 277,081 | 235,932 | |||||||||
| Research and development | 13,485 | 11,562 | 55,530 | 46,365 | |||||||||
| Provision for doubtful accounts and notes receivable | 62 | 88 | 96 | 271 | |||||||||
| Net other operating (income) and restructuring costs | (2,500 | ) | (2,499 | ) | (10,000 | ) | (11,661 | ) | |||||
| Operating income | 25,033 | 23,249 | 160,945 | 128,103 | |||||||||
| Loss/(gain) on foreign currency transactions, net | 2,864 | (3,259 | ) | (5,668 | ) | 7,160 | |||||||
| Loss/(gain) on derivative instruments | 2,140 | (5,965 | ) | 3,302 | (6,102 | ) | |||||||
| Interest expense, net | 1,020 | 843 | 3,883 | 11,043 | |||||||||
| Other expense/(income) | 39 | 1 | (101 | ) | 776 | ||||||||
| Income before taxes | 18,970 | 31,629 | 159,529 | 115,226 | |||||||||
| Income tax provision | 4,821 | 7,061 | 35,744 | 23,780 | |||||||||
| Net income | 14,149 | 24,568 | 123,785 | 91,446 | |||||||||
| Less: Net income attributable to noncontrolling interests | 391 | (130 | ) | 1,992 | 1,457 | ||||||||
| Net income attributable to Sirona Dental Systems, Inc. | $ | 13,758 | $ | 24,698 | $ | 121,793 | $ | 89,989 | |||||
| Income per share (attributable to Sirona Dental Systems, Inc. common shareholders): | |||||||||||||
| - Basic | $ | 0.25 | $ | 0.45 | $ | 2.19 | $ | 1.63 | |||||
| - Diluted | $ | 0.24 | $ | 0.44 | $ | 2.13 | $ | 1.59 | |||||
| Weighted average shares - basic | 56,080,442 | 55,266,337 | 55,735,422 | 55,146,180 | |||||||||
| Weighted average shares - diluted | 57,466,184 | 56,677,680 | 57,292,996 | 56,616,086 | |||||||||
|
SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS |
||||||
| September 30, | September 30, | |||||
| 2011 | 2010 | |||||
| $'000s (except per share amounts) | ||||||
| ASSETS | ||||||
| Current assets | ||||||
| Cash and cash equivalents | $ | 345,859 | $ | 251,767 | ||
| Restricted cash | - | 703 | ||||
| Accounts receivable, net of allowance for doubtful accounts | ||||||
| of $1,868 and $1,681, respectively | 97,853 | 82,952 | ||||
| Inventories, net | 93,028 | 74,027 | ||||
| Deferred tax assets | 25,014 | 20,570 | ||||
| Prepaid expenses and other current assets | 15,477 | 24,139 | ||||
| Income tax receivable | 4,193 | 3,533 | ||||
| Total current assets | 581,424 | 457,691 | ||||
| Property, plant and equipment, net of accumulated depreciation | ||||||
| and amortization of $111,832 and $90,713, respectively | 131,044 | 102,686 | ||||
| Goodwill | 653,799 | 656,465 | ||||
| Investments | 2,453 | 2,317 | ||||
| Restricted cash | 655 | - | ||||
| Intangible assets, net of accumulated amortization of | ||||||
| $412,428 and $371,303, respectively | 346,442 | 362,722 | ||||
| Other non-current assets | 2,884 | 2,229 | ||||
| Deferred tax assets | 7,427 | 8,827 | ||||
| Total assets | $ | 1,726,128 | $ | 1,592,937 | ||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
| Current liabilities | ||||||
| Trade accounts payable | $ | 48,697 | $ | 42,737 | ||
| Short-term debt and current portion of long-term debt | 368,403 | 2,935 | ||||
| Income taxes payable | 6,811 | 7,748 | ||||
| Deferred tax liabilities | 1,108 | 1,456 | ||||
| Accrued liabilities and deferred income | 110,207 | 105,209 | ||||
| Total current liabilities | 535,226 | 160,085 | ||||
| Long-term debt | - | 367,801 | ||||
| Deferred tax liabilities | 138,327 | 138,190 | ||||
| Other non-current liabilities | 16,978 | 6,556 | ||||
| Pension related provisions | 49,677 | 52,672 | ||||
| Deferred income | 50,000 | 60,000 | ||||
| Total liabilities | 790,208 | 785,304 | ||||
| Shareholders' equity | ||||||
|
Preferred stock ($0.01 par value; 5,000,000 shares authorized; |
0 | 0 | ||||
| Common stock ($0.01 par value; 95,000,000 shares authorized; | ||||||
|
56,292,420 shares issued and 55,815,323 shares outstanding at
Sept. 30, 2011; |
563 | 553 | ||||
| Additional paid-in capital | 685,617 | 652,698 | ||||
| Treasury stock (at cost) | ||||||
|
477,097 shares held at cost at Sept. 30, 2011; |
(19,749 | ) | (284 | ) | ||
| Excess of purchase price over predecessor basis | (49,103 | ) | (49,103 | ) | ||
| Retained earnings | 303,639 | 181,846 | ||||
| Accumulated other comprehensive income | 11,309 | 19,701 | ||||
| Total Sirona Dental Systems, Inc. shareholders' equity | 932,276 | 805,411 | ||||
| Noncontrolling interests | 3,644 | 2,222 | ||||
| Total shareholders' equity | 935,920 | 807,633 | ||||
| Total liabilities and shareholders' equity | $ | 1,726,128 | $ | 1,592,937 | ||
|
SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||
| Year ended | Year ended | |||||
| September 30, | September 30, | |||||
| 2011 | 2010 | |||||
| $'000s | ||||||
| Cash flows from operating activities | ||||||
| Net income | $ | 123,785 | $ | 91,446 | ||
|
Adjustments to reconcile net income
|
||||||
| Depreciation and amortization | 81,173 | 82,724 | ||||
| Compensation charge paid by shareholders (Note 25) | 6,625 | - | ||||
| Loss on disposal of property, plant and equipment | - | 1 | ||||
| Loss/(gain) on derivative instruments | 3,302 | (6,102 | ) | |||
| (Gain)/loss on foreign currency transactions | (5,668 | ) | 7,160 | |||
| Deferred income taxes | (17,173 | ) | (21,463 | ) | ||
| Amortization of debt issuance cost | 587 | 1,016 | ||||
| Share-based compensation expense | 7,604 | 13,616 | ||||
| Changes in assets and liabilities | ||||||
| Accounts receivable | (14,202 | ) | 8,800 | |||
| Inventories | (19,542 | ) | (2,541 | ) | ||
| Prepaid expenses and other current assets | 8,861 | 5,532 | ||||
| Restricted cash | 20 | 134 | ||||
| Other non-current assets | (453 | ) | (9,097 | ) | ||
| Trade accounts payable | 6,191 | 6,076 | ||||
| Accrued interest on long-term debt | - | (158 | ) | |||
| Accrued liabilities and deferred income | 2,566 | 2,816 | ||||
| Other non-current liabilities | (2,997 | ) | (7,840 | ) | ||
| Income taxes receivable | (697 | ) | 265 | |||
| Income taxes payable | (1,129 | ) | 3,284 | |||
| Net cash provided by operating activities | $ | 178,853 | $ | 175,669 | ||
| Cash flows from investing activities | ||||||
| Investment in property, plant and equipment | (56,958 | ) | (23,963 | ) | ||
| Proceeds from sale of property, plant and equipment | - | 255 | ||||
| Purchase of intangible assets | (203 | ) | (851 | ) | ||
| Purchase of long-term investments | (145 | ) | (575 | ) | ||
| Acquisition of business, net of cash acquired | (20,836 | ) | - | |||
| Sale of business, net of cash sold | - | 1,928 | ||||
| Net cash used in investing activities | $ | (78,142 | ) | $ | (23,206 | ) |
| Cash flows from financing activities | ||||||
| Repayments of short-term and long-term debt | $ | - | $ | (78,072 | ) | |
| Purchase of treasury stock | (19,465 | ) | - | |||
| Purchase of shares from noncontrolling interest | - | (1,519 | ) | |||
| Dividend distributions to noncontrolling interest | (487 | ) | - | |||
| Common shares issued under share based | ||||||
| compensation plans | 11,138 | 4,097 | ||||
| Tax effect of common shares exercised under share based | ||||||
| compensation plans | 8,501 | 1,562 | ||||
| Net cash used in financing activities | $ | (313 | ) | $ | (73,932 | ) |
| Change in cash and cash equivalents | 100,398 | 78,531 | ||||
| Effect of exchange rate change on cash and cash equivalents | (6,306 | ) | (7,862 | ) | ||
| Cash and cash equivalents at beginning of period | 251,767 | 181,098 | ||||
| Cash and cash equivalents at end of period | $ | 345,859 | $ | 251,767 | ||
|
Non-GAAP Financial Measures (unaudited) |
|||||||||||||||
| Three months ended September 30, 2011 | |||||||||||||||
| Pre Tax | Tax Impact* | After Tax | Per Diluted Share | ||||||||||||
| $'000s | |||||||||||||||
|
GAAP net income attributable to Sirona Dental Systems, Inc. |
$ | 13,758 | $ | 0.24 | |||||||||||
| Adjustments | |||||||||||||||
| Add back non-cash compensation charge | $ | 6,625 | - | 6,625 | |||||||||||
|
Amortization and depreciation expense resulting from the step-up |
$ | 13,531 | $ | 2,716 | $ | 10,815 | |||||||||
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying |
4,216 | 925 | 3,291 | ||||||||||||
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying |
5,664 | 1,241 | 4,423 | ||||||||||||
|
Non-GAAP adjusted net income attributable to Sirona Dental |
$ | 38,912 | $ | 0.68 | |||||||||||
| Note: Effective tax rate, excluding the $6.6 million non-cash compensation expense was 18.8% in 4Q11 | |||||||||||||||
| Full Year ended September 30, 2011 | |||||||||||||||
| Pre Tax | Tax Impact* | After Tax | Per Diluted Share | ||||||||||||
| $'000s | |||||||||||||||
|
GAAP net income attributable to Sirona Dental Systems, Inc. |
$ | 121,793 | $ | 2.13 | |||||||||||
| Adjustments | |||||||||||||||
| Add back non-cash compensation charge | $ | 6,625 | 6,625 | ||||||||||||
|
Amortization and depreciation expense resulting from the step-up |
$ | 53,562 | $ | 11,523 | $ | 42,039 | |||||||||
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying |
499 | 107 | 392 | ||||||||||||
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying |
1,045 | 225 | 820 | ||||||||||||
|
Non-GAAP adjusted net income attributable to Sirona Dental |
$ | 171,669 | $ | 3.00 | |||||||||||
| Note: Effective tax rate, excluding the $6.6 million non-cash payment was 21.5% in FY11 | |||||||||||||||
| Three months ended September 30, 2010 | |||||||||||||||
| Pre Tax | Tax Impact* | After Tax | Per Diluted Share | ||||||||||||
| $'000s | |||||||||||||||
|
GAAP net income attributable to Sirona Dental Systems, Inc. |
$ | 24,697 | $ | 0.44 | |||||||||||
| Adjustments | |||||||||||||||
|
Amortization and depreciation expense resulting from the step-up |
$ | 14,463 | $ | 3,273 | $ | 11,190 | |||||||||
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying |
(7,478 | ) | (1,459 | ) | (6,019 | ) | |||||||||
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying |
(6,398 | ) | (1,247 | ) | (5,151 | ) | |||||||||
|
Non-GAAP adjusted net income attributable to Sirona Dental |
$ | 24,718 | $ | 0.44 | |||||||||||
| Note: Effective tax rate was 22.3% in 4Q11 | |||||||||||||||
| Full Year months ended September 30, 2010 | |||||||||||||||
| Pre Tax | Tax Impact* | After Tax | Per Diluted Share | ||||||||||||
| $'000s | |||||||||||||||
|
GAAP net income attributable to Sirona Dental Systems, Inc. |
$ | 89,989 | $ | 1.59 | |||||||||||
| Adjustments | |||||||||||||||
|
Amortization and depreciation expense resulting from the step-up |
$ | 59,595 | $ | 12,299 | $ | 47,296 | |||||||||
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying |
5,713 | 1,179 | 4,534 | ||||||||||||
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying |
5,108 | 1,054 | 4,054 | ||||||||||||
| Reversal of accrued restructuring expenses | (754 | ) | (156 | ) | (598 | ) | |||||||||
| Gain on sale of business | (908 | ) | (187 | ) | (721 | ) | |||||||||
|
Non-GAAP adjusted net income attributable to Sirona Dental |
$ | 144,553 | $ | 2.55 | |||||||||||
| Note: Effective tax rate 20.6% in FY10 | |||||||||||||||
To supplement our consolidated financial statements and our business outlook, we use the following non-GAAP financial measures: non-GAAP adjusted net income, and non-GAAP adjusted earnings per diluted share, which exclude, as applicable, amortization and depreciation expense resulting from the step-up to fair values of intangible and tangible assets related to past business combinations, unrealized, non-cash loss/(gain) on revaluation of the carrying value of the $-denominated exclusivity fee, unrealized, non-cash loss/(gain) on revaluation of the carrying value of short-term intra-group loans and any related tax effects.
Management recognizes that the use of these non-GAAP measures has limitations, including the fact that they might not be comparable with similar non-GAAP measures used by other companies and that management must exercise judgment in determining which types of charges and other items should be excluded from its non-GAAP financial measures. Management currently compensates for these limitations by providing full disclosure of each non-GAAP financial measure and a reconciliation to the most directly comparable GAAP measure. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.
We use these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our "core operating performance". Management believes that "core operating performance" represents Sirona’s operating performance in the ordinary, ongoing and customary course of its operations. Accordingly, management excludes from "core operating performance" the impact of acquisition-related intangible depreciation and amortization in order to compare our underlying financial performance to prior periods, certain non-cash charges related to currency revaluation that do not reflect our period-to-period operating performance, and to the extent relevant in a particular period, any other cash or non-cash items that management does not view as indicative of its on-going operating performance. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate management's internal evaluation of period-to-period comparisons. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making and (2) they are provided to and used by our institutional investors and the analyst community to facilitate comparisons with prior and subsequent reporting periods.
Constant Currency: We have included certain revenue information in this press release on a constant currency basis. This information is a non-GAAP financial measure. We supplementally present revenue on a constant currency basis because we believe it facilitates a comparison of our operating results from period to period without regard to changes resulting solely from fluctuations in currency rates.
The average exchange rate for the three months ended September 30, 2011, was $1.41653. The average exchange rate for the fiscal year ended September 30, 2011, was $1.39570 and varied from $1.44395 to $1.30339. For the three months and full year ended September 30, 2010, an average exchange rate converting Euro denominated revenues into U.S. Dollars of $1.29021 and $1.35730, respectively, was applied.